James R. Gillard
H3T1J4, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Drug Self-Aggregation into Nano-Entities Has the Potential to Induce Immune Responses.
Journal: Molecular pharmaceutics
Published: July 08, 2023
Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.
Journal: ACS medicinal chemistry letters
Published: February 11, 2016
Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.
Journal: Journal of medicinal chemistry
Published: November 14, 2014
Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127).
Journal: Journal of medicinal chemistry
Published: October 29, 2013
Enantiomeric atropisomers inhibit HCV polymerase and/or HIV matrix: characterizing hindered bond rotations and target selectivity.
Journal: Journal of medicinal chemistry
Published: September 13, 2013
Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency.
Journal: Journal of medicinal chemistry
Published: June 19, 2013
Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists.
Journal: Journal of medicinal chemistry
Published: June 05, 2013
N- versus O-alkylation: utilizing NMR methods to establish reliable primary structure determinations for drug discovery.
Journal: Bioorganic & medicinal chemistry letters
Published: January 26, 2013
Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).
Journal: Journal of medicinal chemistry
Published: August 02, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026